Physician profile
Amy R Cunningham
NPI 1902855661
$5,931.16
in general payments reported to CMS, 2019-2025
36 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $747 · 2021: $1,192 · 2022: $1,227 · 2023: $1,351 · 2024: $674 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,437.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.83 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $779.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $705.37 | 2020-2025 | |
| Amgen INC. | $523.72 | 2019-2024 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $511.72 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $421.26 | 2019-2024 | Breztri, Flumist Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $244.26 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.48 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $209.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $204.29 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.43 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $142.09 | 2019-2023 | Gardasil 9, M-M-R II, Rotateq |
| Biohaven Pharmaceutical Holding Company LTD. | $121.10 | 2022 | |
| Organogenesis INC. | $108.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $82.88 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $74.78 | 2021-2023 | Dexcom G7 Gss (161) |
| Allergan, INC. | $74.53 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.28 | 2019-2022 | |
| Astellas Pharma US INC | $54.07 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $50.90 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.98 | 2025 | Caplyta |
| Eisai INC. | $38.63 | 2020-2021 | |
| Sanofi Pasteur INC. | $36.80 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $36.57 | 2020-2021 | |
| Radius Health, INC. | $35.33 | 2019-2022 | |
| Biogen, INC. | $24.61 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $23.70 | 2021 | |
| Smith+Nephew, INC. | $22.56 | 2019-2020 | |
| Convatec INC. | $17.97 | 2024 | |
| Averitas Pharma INC. | $17.01 | 2023 | Qutenza |
| Esperion Therapeutics, INC. | $16.31 | 2021 | |
| Grifols USA, LLC | $16.08 | 2021 | |
| Neos Therapeutics, LP | $14.92 | 2021 | |
| Exact Sciences Corporation | $13.71 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $12.67 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.